Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-03-23 | Dominick Colangelo has served as a director and as Vericel’s President and Chief Executive Officer since March 2013. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2022. Mr. Colangelo’s compensation from the Company for 2022 is set forth in the 2022 Summary Compensation Table. Mr. Colangelo did not receive any additional compensation for his service as a director. His total compensation for 2022 was $8,708,367. |
| 2024-03-21 | Dominick Colangelo, 60, President and Chief Executive Officer, Vericel, Director Since: 2013, Other Current Public Company Directorships: Trevi Therapeutics, Inc., Vericel Board committee(s): None, Total compensation in 2023: $7,056,422 |
| 2025-03-20 | Dominick Colangelo, 61 President and Chief Executive Officer, Vericel Director Since: 2013 Vericel Board committee(s): None Mr. Colangelo’s compensation from the Company for 2024 is set forth in the 2024 Summary Compensation Table. Mr. Colangelo did not receive any additional compensation for his service as a director. |
Data sourced from SEC filings. Last updated: 2026-02-03